Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
IRIDEX Q4 2025 Earnings Call - Turnaround Delivers Positive Adjusted EBITDA and Q4 Cash Flow, Margin Fix Is Work in Progress
IRIDEX closed 2025 with a clear glidepath to profitability: full-year revenue of $52.7 million (up 8% YoY), positive adjusted EBITDA for the first time in recent history, and positive operating cash f...
- Full-year 2025 revenue was $52.7 million, up 8% year-over-year versus 2024.
- IRIDEX achieved positive adjusted EBITDA for full-year 2025 and generated positive operating cash flow in Q4 2025.
- Q4 2025 revenue was $14.7 million, a 16% year-over-year increase driven by higher retina and glaucoma probe sales.
- +15 more takeaways
Blink Charging Co. Q4 2025 Earnings Call - Restructured to Cut Burn to $2M/Quarter and Shift to Recurring Service Revenue
Blink’s Q4 and full year 2025 call was a report card on survival and reset. The Blink Forward program materially reshaped the company, halving headcount, exiting in-house manufacturing, taking a one-t...
- Blink Forward delivered a material reset, the company says it substantially met its 2025 objectives and repositioned Blink as a leaner, financially focused business.
- Headcount was cut from roughly 600 employees at the start of 2025 to fewer than 300 today, part of a drive to right-size the cost base.
- Blink completed its shift to contract manufacturing, exiting in-house production to reduce working capital intensity and supply chain complexity.
- +15 more takeaways
Daré Bioscience FY2025 Earnings Call - DARE to PLAY pre-fulfillment live nationwide, revenue expected Q2 2026
Daré presented a clear, execution-focused year end 2025 update, pivoting from R&D heavy years into commercial activation. The headline is DARE to PLAY, a GMP-made topical sildenafil cream backed by pu...
- DARE to PLAY, a topical sildenafil cream with published clinical data showing increased genital blood flow within 10-15 minutes, went live for pre-fulfillment prescriptions in all 50 states as of February 11, 2026.
- Telehealth access for DARE to PLAY launched alongside pre-fulfillment, enabling remote prescribing; dispensing will begin once the 503B outsourcing facility completes state licensing and fulfillment preparations.
- Daré is using a dual path commercial strategy: immediate 503B compounding to generate prescriptions and real-world data, while simultaneously pursuing a 505(b)(2) NDA for the sildenafil cream.
- +12 more takeaways
Newsmax Fourth Quarter and Fiscal Year 2025 Earnings Call - Affiliate Fee Repricing and Distribution to Propel 2026 Growth
Newsmax closed its first year as a public company with full-year revenue of $189.3 million, up 10.7%, driven by a 17.3% jump in broadcasting revenue and a 14.9% rise in affiliate fees. Management is p...
- Full-year 2025 revenue $189.3 million, up 10.7% year-over-year, at the high end of guidance.
- Broadcasting revenue was the growth engine, up 17.3% to $153.3 million for FY2025.
- Affiliate fees rose 14.9% year-over-year to $30.6 million, and management expects affiliate fee repricing and renewals to be the primary driver of 2026 growth.
- +14 more takeaways
Alpha Cognition Q4 2025 Earnings Call - ZUNVEYL adoption accelerates in long-term care, payer access remains the gatekeeper
Alpha Cognition reported early but tangible commercial traction for ZUNVEYL, with sequential demand gains concentrated in the long-term care market. Dispensed volume, repeat prescribing, and clinic re...
- Q4 2025 net product revenue from ZUNVEYL was $2.5 million, total Q4 revenue $2.8 million, and full-year 2025 revenue was $10.2 million with $6.8 million from product sales.
- Demand momentum: 4,941 bottles dispensed in Q4, with 1,859 bottles in December, the strongest month since launch.
- Commercial reach expanded to roughly 3,856 unique long-term care homes launched to date, and the sales team engaged nearly 2,000 nursing homes in Q4.
- +16 more takeaways
SKYX Platforms Q4 2025 Earnings Call - Turbo Heater, retailer rollouts and $29M raise set target to reach cash flow positive
SKYX posted a record $92 million in 2025 revenue, marking eight consecutive quarters of year-over-year growth and three straight years of annual revenue gains. Gross profit rose to $28 million and gro...
- Company reported record 2025 revenue of $92.0 million, continuing eight consecutive quarters of year-over-year revenue growth and three years of annual growth.
- Gross profit increased to $28.0 million in 2025, up $3.0 million or 13% year over year, and gross margin rose to 30% from 28%.
- Operating cash used in 2025 narrowed to $13.0 million versus $18.0 million in 2024, a 27% reduction in cash burn from operations.
- +13 more takeaways
P3 Health Partners Fourth Quarter 2025 Earnings Call - Contracts and CMS rate lifts support $170M EBITDA improvement to positive in 2026
P3 Health wrapped 2025 with heavy lifting behind the scenes and a clear claim for 2026: move from a full-year Adjusted EBITDA loss of $161.3 million to a midpoint profit target of $10 million. Managem...
- Company guides 2026 Adjusted EBITDA to a range of -$20 million to $40 million, with a midpoint of $10 million, versus a 2025 Adjusted EBITDA loss of $161.3 million.
- Management identified $170 million of structural and operational improvement opportunities to bridge 2025 to 2026, split into $125 million (75%) from contracting and revenue actions, $35 million (20%) from operational MedEx and network contracting, and $10 million (5%) from payer benefit design and membership mix.
- About 75% of the $170 million improvement is run-rated as of January 2026, driven largely by contract renegotiations and CMS benchmark increases, management says.
- +11 more takeaways
VirTra Q4 and Full Year 2025 Earnings Call - Funding Freeze Delayed Revenue, Demand Intact as Grants Reopen
VirTra says 2025 was defined by an extended federal funding freeze that delayed awards, procurement and deliveries, compressing reported revenue even as demand continued. Management reports $26.7 mill...
- Federal funding freeze that began in 2024 materially delayed FY2025 awards and procurement, suppressing revenue recognition through 2025.
- Q4 2025 revenue was $2.9 million, down from $4.7 million year-over-year, driven by deferred deliveries and funding timing.
- Full-year 2025 revenue was $22.4 million, compared to $26.4 million in 2024, a decline attributed primarily to extended funding delays.
- +13 more takeaways
CapsoVision Q4 2025 Earnings Call - Pivot to CapsoCam Colon Gen2 and AI as Small-Bowel Adoption Grows
CapsoVision closed 2025 with steady commercial traction in its CapsoCam Plus small-bowel capsule, modest top-line growth, and a clear shift of R&D resources toward a higher-spec CapsoCam Colon Gen 2 a...
- CapsoVision reported full-year revenue growth of approximately 15% year-over-year and a 21% increase in new account generation for 2025.
- Installed base exceeded 161,000 patients imaged with CapsoCam Plus as of December 31, 2025.
- Fourth quarter 2025 revenue was $3.9 million, up 13% versus Q4 2024; about 9,400 patients used CapsoCam Plus in Q4, a 12% year-over-year increase from ~8,374.
- +12 more takeaways
Rani Therapeutics Q4 2025 and Full Year 2025 Earnings Call - RT-114 Enters Phase I-B, first human PD test of RaniPill that could validate the platform
Rani closed 2025 with a string of strategic moves and a clear bet: prove the RaniPill works not just for pharmacokinetics, but for pharmacodynamics in humans. The company signed a collaboration with C...
- Rani signed a collaboration and license agreement with Chugai in October 2025, potential total value approximately $1.1 billion, including an option for Chugai to expand to up to five additional targets.
- Concurrent with the Chugai deal, Rani closed an oversubscribed $60.3 million private placement, including $6 million of debt conversion led by life science investors.
- Cash and marketable securities were $49.7 million as of December 31, 2025, up from $27.6 million at year-end 2024.
- +12 more takeaways